Testosterone Therapy Heart Risk in Women: Evidence Guide

Testosterone therapy did not increase heart rate or worsen cardiovascular risk markers in a 24-week randomized, placebo-controlled study of hysterectomized women. Whether TRT is worth it for you depends on the reason it is being considered, your dose and route, and your own heart and blood-vessel history—not on a single headline.

The heart question is easiest to understand when you separate a measured result from a percentage claim. In the women’s trial, researchers compared testosterone with placebo (a look-alike treatment with no active hormone) over 24 weeks and found no meaningful between-group change in blood pressure or heart rate. Higher naturally occurring testosterone levels in postmenopausal women have also been associated with insulin resistance, metabolic syndrome and coronary heart disease in observational research, which is why the decision needs to account for your whole risk picture.

Does testosterone increase heart rate in women?

Not in the 24-week randomized trial summarized in this NIH-hosted review. Across a range of testosterone doses, heart rate and blood pressure did not differ from placebo. A randomized trial assigns people to treatments by chance, making it useful for comparing outcomes during the study period.

That finding answers the specific resting-heart-rate question better than an anecdote can: it is reassuring for the women studied, while a heart-rate reading is still only one part of cardiovascular health.

Can high testosterone cause heart problems in females?

Higher testosterone measured in postmenopausal women has been associated with insulin resistance, metabolic syndrome, visceral fat and coronary heart disease in observational studies. An observational study can identify patterns among people; it cannot tell you that the hormone level itself caused the outcome. In the same review, the 24-week intervention study found no worsening in the cardiovascular markers it measured.

Long-term cardiovascular safety of testosterone therapy in women needs further study.

What do the numbers behind a heart-risk claim mean?

Research in men is often used in testosterone headlines, but it is not a substitute for women’s data. Cleveland Clinic describes a randomized trial of about 5,000 men ages 45 to 80 with documented low testosterone: participants used testosterone gel or placebo, received treatment for an average of 22 months and were followed for 33 months. Heart-related events occurred in 7.0% of the testosterone group and 7.3% of the placebo group.

Here is the small worked example: 7.0 events per 100 people versus 7.3 per 100 is an absolute difference of 0.3 events per 100 people, or three per 1,000. The relative difference sounds like about 4% lower with testosterone, but the absolute difference shows how close the two observed rates were. Our guide to relative risk vs absolute risk explains why both ways of describing a result matter.

Cleveland Clinic’s trial summary is useful context for the 7.0% and 7.3% figures, but its participants were men with two low testosterone measurements and symptoms, not women considering therapy.

Can you use HRT if you have heart disease?

Hormone therapy (HT) usually refers to menopausal treatment with estrogen, sometimes combined with a progestogen; it is not the same treatment question as testosterone alone. A Cleveland Clinic summary of an American College of Cardiology review places women with established atherosclerotic cardiovascular disease, coronary or peripheral artery disease, prior heart attack, stroke or transient ischemic attack, venous thromboembolism, pulmonary embolism, or a 10-year ASCVD risk of 10% or more in a high-risk group for menopausal HT.

The same review describes women with a 10-year ASCVD risk below 5% and recent menopause as low risk, and those with risk factors such as diabetes, smoking, high blood pressure, obesity, high cholesterol or a 5% to 10% ASCVD risk as intermediate risk. ASCVD means atherosclerotic cardiovascular disease—plaque-related disease of the heart or blood vessels. You can use the categories to have a more specific conversation than simply asking whether “hormones are safe.”

For some intermediate- or high-risk situations, the review says transdermal estrogen, progestogens or vaginal estrogen may be a better fit than oral estrogen; observational research suggests lower venous-thromboembolism risk with transdermal versus oral HT. Read the menopausal HT heart-risk guidance before that conversation.

Is progesterone safe for heart patients?

Progesterone and progestogens are not interchangeable labels in every regimen. The cardiovascular review discusses progestogens as one option that may be considered alongside non-oral estrogen routes for some people at intermediate or high risk. Bring the exact product name, route and dose to the appointment, along with any history of heart attack, stent, stroke, clot, high blood pressure or high cholesterol.

Why might someone feel better on testosterone?

Feeling more energetic or better overall can be real to the person experiencing it, but it does not measure heart risk. In women, trials cited in the NIH-hosted review reported improved sexual function with transdermal testosterone that raised blood levels into the mid-to-high normal range for healthy young women. That is a different outcome from facial aging, sagging skin, tiredness from a high dose, or a heart-rate change.

The practical next step is to define what “working” means before treatment starts: the symptom you want to track, the time period, the measurement that matters and the point at which the plan will be reassessed. That keeps a good early feeling from becoming the only signal used to judge dose or safety.

Questions that need a personal plan

Insurance coverage, changes after stopping testosterone, facial aging, sagging skin, tiredness with a high level and low testosterone’s effect on heart rate all depend on the particular prescription, diagnosis and health history. Take these focused questions with you:

• What is the goal of testosterone in my case, and how will we measure whether it is helping?
• What is my 10-year ASCVD risk, and which parts of my history change the hormone decision?
• Could my current medicines, blood pressure, lipids or clot history affect the plan?
• Which route and dose are being considered, and why?
• What should I expect if the dose changes or therapy stops?
• Will my insurer cover this prescription, and what documentation does it require?

These questions also help distinguish a large relative-risk claim from the change that would matter in everyday terms. For a deeper way to read a harm claim, see number needed to harm.

By the Everyday Prevention Evidence Team